Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05TPI
|
|||
| Former ID |
DNC013888
|
|||
| Drug Name |
EPICATECHIN
|
|||
| Synonyms |
(-)-Epicatechin; Epicatechin; 490-46-0; L-Epicatechin; (-)-Epicatechol; l-Acacatechin; (2R,3R)-2-(3,4-Dihydroxyphenyl)chroman-3,5,7-triol; Epicatechol; l-Epicatechol; (-)epicatechin; (2R,3R)-(-)-Epicatechin; UNII-34PHS7TU43; epi-Catechin; epi-Catechol; CCRIS 7097; EINECS 207-710-1; NSC 81161; Epicatechol, (-)-; CHEBI:90; 34PHS7TU43; PFTAWBLQPZVEMU-UKRRQHHQSA-N; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol; (-)-(2R:3R)-5,7,3',4'-Tetrahydroxyflavan-3-ol; AK105372; C15H14O6
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 1/2 | [1] | |
| Friedreich's ataxia [ICD-11: 8A03.10; ICD-9: 334] | Phase 1/2 | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H14O6
|
|||
| Canonical SMILES |
C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)O
|
|||
| InChI |
1S/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15-/m1/s1
|
|||
| InChIKey |
PFTAWBLQPZVEMU-UKRRQHHQSA-N
|
|||
| CAS Number |
CAS 17334-50-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:90
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [2] | |||
| Metabolic Reaction | C-ring cleavage | |||
| Resulting Metabolite | Phenolic acids | |||
| Description | Epicatechin can be metabolized to Phenolic acids by gut microbiota through C-ring cleavage. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mitochondrial protein unspecific (MP) | Target Info | Modulator | [1] |
| Oxidoreductase unspecific (OR) | Target Info | Modulator | [1] | |
| Prostaglandin G/H synthase 1 (COX-1) | Target Info | Inhibitor | [3] | |
| BioCyc | C20 prostanoid biosynthesis | |||
| KEGG Pathway | Arachidonic acid metabolism | |||
| Metabolic pathways | ||||
| Platelet activation | ||||
| Serotonergic synapse | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Pathwhiz Pathway | Arachidonic Acid Metabolism | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Arachidonic acid metabolism | ||||
| Phase 1 - Functionalization of compounds | ||||
| Eicosanoid Synthesis | ||||
| Selenium Micronutrient Network | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Gut Microbiota-Mediated Drug-Antibiotic Interactions. Drug Metab Dispos. 2015 Oct;43(10):1581-9. | |||
| REF 3 | Mechanism-based inactivation of COX-1 by red wine m-hydroquinones: a structure-activity relationship study. J Nat Prod. 2004 Nov;67(11):1777-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.